PL2049671T3 - Regulatorowe elementy kwasu nukleinowego - Google Patents

Regulatorowe elementy kwasu nukleinowego

Info

Publication number
PL2049671T3
PL2049671T3 PL07730192T PL07730192T PL2049671T3 PL 2049671 T3 PL2049671 T3 PL 2049671T3 PL 07730192 T PL07730192 T PL 07730192T PL 07730192 T PL07730192 T PL 07730192T PL 2049671 T3 PL2049671 T3 PL 2049671T3
Authority
PL
Poland
Prior art keywords
nucleic acid
regulatory nucleic
acid elements
elements
regulatory
Prior art date
Application number
PL07730192T
Other languages
English (en)
Inventor
Barbara Enenkel
Kerstin Sautter
Original Assignee
Boehringer Ingelheim Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Pharma filed Critical Boehringer Ingelheim Pharma
Publication of PL2049671T3 publication Critical patent/PL2049671T3/pl

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/67General methods for enhancing the expression
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00Nucleic acids vectors
    • C12N2800/10Plasmid DNA
    • C12N2800/106Plasmid DNA for vertebrates
    • C12N2800/107Plasmid DNA for vertebrates for mammalian
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00Vector systems having a special element relevant for transcription
    • C12N2830/46Vector systems having a special element relevant for transcription elements influencing chromatin structure, e.g. scaffold/matrix attachment region, methylation free island
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00Vector systems having a special element relevant for transcription
    • C12N2830/80Vector systems having a special element relevant for transcription from vertebrates
    • C12N2830/85Vector systems having a special element relevant for transcription from vertebrates mammalian
PL07730192T 2006-07-26 2007-06-15 Regulatorowe elementy kwasu nukleinowego PL2049671T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP06117862 2006-07-26
EP07730192A EP2049671B1 (de) 2006-07-26 2007-06-15 Regulatorische nukleinsäureelemente
PCT/EP2007/055954 WO2008012142A1 (de) 2006-07-26 2007-06-15 Regulatorische nukleinsäureelemente

Publications (1)

Publication Number Publication Date
PL2049671T3 true PL2049671T3 (pl) 2013-05-31

Family

ID=37441548

Family Applications (1)

Application Number Title Priority Date Filing Date
PL07730192T PL2049671T3 (pl) 2006-07-26 2007-06-15 Regulatorowe elementy kwasu nukleinowego

Country Status (23)

Country Link
US (3) US20080124760A1 (pl)
EP (1) EP2049671B1 (pl)
JP (1) JP5270544B2 (pl)
KR (1) KR101485853B1 (pl)
CN (1) CN101517085B (pl)
AR (1) AR061472A1 (pl)
AU (1) AU2007278368B2 (pl)
BR (1) BRPI0714594A2 (pl)
CA (1) CA2658595C (pl)
CY (1) CY1113711T1 (pl)
DK (1) DK2049671T3 (pl)
EA (1) EA016880B1 (pl)
ES (1) ES2401654T3 (pl)
HK (1) HK1134107A1 (pl)
IL (1) IL196676A0 (pl)
MX (1) MX2009000781A (pl)
NO (1) NO20090057L (pl)
NZ (1) NZ575115A (pl)
PL (1) PL2049671T3 (pl)
PT (1) PT2049671E (pl)
SI (1) SI2049671T1 (pl)
TW (1) TW200815591A (pl)
WO (1) WO2008012142A1 (pl)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120258496A1 (en) 2010-09-27 2012-10-11 Boehringer Ingelheim International Gmbh Production of low fucose antibodies in h4-ii-e rat cells
CN103620034B (zh) 2011-04-13 2016-12-14 加拿大国家研究委员会 具有来自IFNα2的SAR元件的表达系统
JP5775974B2 (ja) 2011-10-28 2015-09-09 プロセナ バイオサイエンシーズ リミテッド アルファシヌクレインを認識するヒト化抗体
WO2013112945A1 (en) 2012-01-27 2013-08-01 Neotope Biosciences Limited Humanized antibodies that recognize alpha-synuclein
UA118441C2 (uk) 2012-10-08 2019-01-25 Протена Біосаєнсиз Лімітед Антитіло, що розпізнає альфа-синуклеїн
PE20152004A1 (es) 2013-03-13 2016-02-07 Prothena Biosciences Ltd Inmunoterapia tau
US10513555B2 (en) 2013-07-04 2019-12-24 Prothena Biosciences Limited Antibody formulations and methods
WO2015004632A1 (en) 2013-07-12 2015-01-15 Neotope Biosciences Limited Antibodies that recognize iapp
WO2015004633A1 (en) 2013-07-12 2015-01-15 Neotope Biosciences Limited Antibodies that recognize islet-amyloid polypeptide (iapp)
WO2015075635A2 (en) 2013-11-19 2015-05-28 Prothena Biosciences Limited Monitoring immunotherapy of lewy body disease from constipation symptoms
CA2938933A1 (en) 2014-03-12 2015-09-17 Prothena Biosciences Limited Anti-laminin4 antibodies specific for lg4-5
KR20160131082A (ko) 2014-03-12 2016-11-15 프로테나 바이오사이언시즈 리미티드 Lg1-3에 특이적인 항-라미닌4 항체
TW201623331A (zh) 2014-03-12 2016-07-01 普羅帝納生物科學公司 抗黑色素瘤細胞黏著分子(mcam)抗體類及使用彼等之相關方法
PT3116911T (pt) 2014-03-12 2019-09-04 Prothena Biosciences Ltd Anticorpos anti-mcam e métodos de utilização associados
EP3129051A1 (en) 2014-04-08 2017-02-15 Prothena Biosciences Limited Blood-brain barrier shuttles containing antibodies recognizing alpha-synuclein
TWI769570B (zh) 2015-01-28 2022-07-01 愛爾蘭商普羅佘納生物科技有限公司 抗甲狀腺素運送蛋白抗體
TWI718122B (zh) 2015-01-28 2021-02-11 愛爾蘭商普羅佘納生物科技有限公司 抗甲狀腺素運送蛋白抗體
TWI718121B (zh) 2015-01-28 2021-02-11 愛爾蘭商普羅佘納生物科技有限公司 抗甲狀腺素運送蛋白抗體
AU2016215454B2 (en) * 2015-02-02 2022-05-19 Meiragtx Uk Ii Limited Regulation of gene expression by aptamer-mediated modulation of alternative splicing
WO2017046774A2 (en) 2015-09-16 2017-03-23 Prothena Biosciences Limited Use of anti-mcam antibodies for treatment or prophylaxis of giant cell arteritis, polymyalgia rheumatica or takayasu's arteritis
WO2017046776A2 (en) 2015-09-16 2017-03-23 Prothena Biosciences Limited Use of anti-mcam antibodies for treatment or prophylaxis of giant cell arteritis, polymyalgia rheumatica or takayasu's arteritis
WO2017149513A1 (en) 2016-03-03 2017-09-08 Prothena Biosciences Limited Anti-mcam antibodies and associated methods of use
WO2017153955A1 (en) 2016-03-09 2017-09-14 Prothena Biosciences Limited Use of anti-mcam antibodies for treatment or prophylaxis of granulomatous lung diseases
WO2017153953A1 (en) 2016-03-09 2017-09-14 Prothena Biosciences Limited Use of anti-mcam antibodies for treatment or prophylaxis of granulomatous lung diseases
CU24537B1 (es) 2016-05-02 2021-07-02 Prothena Biosciences Ltd Anticuerpos monoclonales que compiten por unirse a tau humano con el anticuerpo 3d6
PE20190208A1 (es) 2016-05-02 2019-02-07 Prothena Biosciences Ltd Anticuerpos que reconocen tau
KR102506091B1 (ko) 2016-05-02 2023-03-07 프로테나 바이오사이언시즈 리미티드 타우 면역요법
WO2017208210A1 (en) 2016-06-03 2017-12-07 Prothena Biosciences Limited Anti-mcam antibodies and associated methods of use
JP7016470B2 (ja) 2016-07-02 2022-02-07 プロセナ バイオサイエンシーズ リミテッド 抗トランスサイレチン抗体
WO2018007922A2 (en) 2016-07-02 2018-01-11 Prothena Biosciences Limited Anti-transthyretin antibodies
EP3478716A2 (en) 2016-07-02 2019-05-08 Prothena Biosciences Limited Anti-transthyretin antibodies
AU2018263935A1 (en) 2017-05-02 2019-12-19 Prothena Biosciences Limited Antibodies recognizing tau
WO2019064053A1 (en) 2017-09-28 2019-04-04 Prothena Biosciences Limited DOSAGE REGIMES FOR THE TREATMENT OF SYNUCLEINOPATHIES
WO2020034097A1 (en) * 2018-08-14 2020-02-20 Wuxi Biologics (Shanghai) Co., Ltd. Transcriptional regulatory element and its use in enhancing the expression of exogenous protein
KR20210094610A (ko) 2018-11-26 2021-07-29 포티 세븐, 인코포레이티드 c-Kit에 대한 인간화 항체
JP2022524588A (ja) 2019-03-03 2022-05-09 プロセナ バイオサイエンシーズ リミテッド タウ認識抗体
JP7412860B2 (ja) 2020-10-16 2024-01-15 株式会社奥村組 泥水式シールド掘進機および泥水式シールド掘進機における圧縮空気の圧力調整方法
JP2024516153A (ja) * 2021-04-21 2024-04-12 ヤンセン バイオテツク,インコーポレーテツド 改良されたホスホトランスフェラーゼのための材料及び方法

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0173552B1 (en) 1984-08-24 1991-10-09 The Upjohn Company Recombinant dna compounds and the expression of polypeptides such as tpa
DE59010941D1 (de) 1989-04-21 2005-03-24 Amgen Inc TNF-Rezeptor, TNF bindende Proteine und dafür kodierende DNAs
ATE159548T1 (de) 1990-11-13 1997-11-15 Immunex Corp Bifunktionelle wählbare fusionsgene
US5786166A (en) 1991-10-25 1998-07-28 University Of Tennessee Research Corporation Methods for determining effects of a compound on the activity of bacterial periplasmic oxidoreductase enzymes
DE4228458A1 (de) 1992-08-27 1994-06-01 Beiersdorf Ag Multicistronische Expressionseinheiten und deren Verwendung
WO1994028143A1 (en) 1993-05-21 1994-12-08 Targeted Genetics Corporation Bifunctional selectable fusion genes based on the cytosine deaminase (cd) gene
DE19539493A1 (de) * 1995-10-24 1997-04-30 Thomae Gmbh Dr K Starker homologer Promotor aus Hamster
PT873405E (pt) 1996-01-11 2005-01-31 Immunex Corp Elementos de sequencia que aumentam a expressao (ease) para sistemas de expressao eucarioticos
WO2000034320A1 (en) 1998-12-11 2000-06-15 Clontech Laboratories, Inc. Fluorescent proteins from non-bioluminiscent species of class anthozoa, genes encoding such proteins and uses thereof
WO2000034326A1 (en) 1998-12-11 2000-06-15 Clontech Laboratories, Inc. Fluorescent proteins from non-bioluminescent species of class anthozoa, genes encoding such proteins and uses thereof
WO2000034325A1 (en) 1998-12-11 2000-06-15 Clontech Laboratories, Inc. Fluorescent proteins from non-bioluminescent species of class anthozoa, genes encoding such proteins and uses thereof
AUPP967999A0 (en) * 1999-04-09 1999-05-06 North Western Health Care Network Viral variants
CA2385102A1 (en) 1999-07-12 2001-01-18 Genentech, Inc. Expression vectors and methods
JP2003527833A (ja) 1999-10-14 2003-09-24 クロンテック・ラボラトリーズ・インコーポレーテッド 花虫類に由来する発色団/蛍光体、およびそれらの使用法
CN1500147B (zh) 2001-04-05 2011-05-04 密理博公司 改进的基因表达
DE60236331D1 (de) 2001-07-04 2010-06-17 Chromagenics Bv DNS-Sequenzen mit Anti-Repressor-Aktivität
US7344886B2 (en) * 2002-11-29 2008-03-18 Boehringer Ingelheim Pharma Gmbh & Co., Kg Neomycin-phosphotransferase-genes and methods for the selection of recombinant cells producing high levels of a desired gene product
DE10256083A1 (de) * 2002-11-29 2004-08-12 Boehringer Ingelheim Pharma Gmbh & Co. Kg Expressionsvektor, Verfahren zur Herstellung von heterologen Genprodukten und Selektionsverfahren für hochproduzierende rekombinante Zellen
US7384744B2 (en) * 2002-11-29 2008-06-10 Boehringer Ingelheim Pharma Gmbh & Co., Kg Expression vector, methods for the production of heterologous gene products and for the selection of recombinant cells producing high levels of such products
ES2293096T3 (es) 2002-11-29 2008-03-16 BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG Nuevos genes de la fosfotransferasa de neomicina y procedimiento para la seleccion de celulas recombinantes de produccion elevada.

Also Published As

Publication number Publication date
EA200900212A1 (ru) 2009-10-30
EP2049671A1 (de) 2009-04-22
SI2049671T1 (sl) 2013-04-30
BRPI0714594A2 (pt) 2013-02-19
MX2009000781A (es) 2009-01-29
AR061472A1 (es) 2008-08-27
CN101517085B (zh) 2013-08-07
JP5270544B2 (ja) 2013-08-21
CA2658595A1 (en) 2008-01-31
AU2007278368A1 (en) 2008-01-31
HK1134107A1 (en) 2010-04-16
AU2007278368B2 (en) 2013-12-19
CY1113711T1 (el) 2016-06-22
JP2009544293A (ja) 2009-12-17
TW200815591A (en) 2008-04-01
NO20090057L (no) 2009-02-16
US20080124760A1 (en) 2008-05-29
NZ575115A (en) 2011-10-28
US20150337333A1 (en) 2015-11-26
CN101517085A (zh) 2009-08-26
EA016880B1 (ru) 2012-08-30
CA2658595C (en) 2016-05-31
KR101485853B1 (ko) 2015-01-23
IL196676A0 (en) 2011-08-01
EP2049671B1 (de) 2012-12-19
US20100311121A1 (en) 2010-12-09
DK2049671T3 (da) 2013-04-08
US9708626B2 (en) 2017-07-18
WO2008012142A1 (de) 2008-01-31
ES2401654T3 (es) 2013-04-23
PT2049671E (pt) 2013-01-24
KR20090046887A (ko) 2009-05-11
US9045776B2 (en) 2015-06-02

Similar Documents

Publication Publication Date Title
HK1134107A1 (en) Regulatory nucleic acid elements
GB0603160D0 (en) Nucleic acid
GB0703996D0 (en) Nucleic acid detection
EP2207896A4 (en) AMPLIFICATION OF NUCLEIC ACID
EP2123752A4 (en) NOVEL NUCLEIC ACID
GB0706243D0 (en) Modified nucleic acids
HK1126824A1 (en) Integrated nucleic acid assays
HK1149298A1 (en) Methods for nucleic acid sequencing
EP2201021A4 (en) METHOD OF ALTERNATING NUCLEIC ACID SEQUENCING
GB2445441B (en) Nucleic acid purification method
EP2077326A4 (en) NOVEL NUCLEIC ACID
EP1996730A4 (en) CLEANING OF SMALL RNA
GB0717591D0 (en) Nucleic acid purification method
HK1122783A1 (en) Lift system
SG10201500691UA (en) Nucleic acid concatenation
EP2167519A4 (en) NUCLEIC ACID ENCAPSIDATION SYSTEM
GB0522578D0 (en) Ribozymal nucleic acid
ZA200708154B (en) Nucleic acid detection
HK1122780A1 (en) Lift system
EP2072498A4 (en) N-PHENYLOXAMIDE ACID DERIVATIVE
EP2128136A4 (en) DERIVATIVE OF 2-PHENYLNICOTINIC ACID
GB0602718D0 (en) Nucleic Acid Manipulation
GB0602625D0 (en) DNA structures
GB0605321D0 (en) Nucleic acid molecules
GB0607546D0 (en) Nucleic acid sequence detection